Free shipping on all orders over $ 500

CDK Cyclin-dependent kinase


Cat.No.  Name Information
M1806 PD 0332991 HCL PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.
M1974 Roscovitine (Seliciclib) Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
M1764 PF-477736 PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively.
M2112 LY2835219 mesylate LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
M1807 SCH727965 (dinaciclib) SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively.
M21409 FN-1501 FN-1501 is a potent inhibitor of Fms-like receptor tyrosine kinase 3 (FLT3) and cyclin-dependent kinase (CDK), and the IC50 for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3 with IC50s of 2.47, 0.85, 1.96 and 0.28 nM, respectively.
M21223 DS96432529 DS96432529 is a potent bone anabolic agent with oral activity and CDK8 inhibitory activity.
M21221 SY-5609 The CDK7 kinase inhibitor SY-5609 is a picomolar, reversible, highly selective molecule with slow off-rate kinetics. SY-5609 has a weak inhibitory effect on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), and CDK12 (Ki=870 nM).
M21214 AS-0141 AS-0141 (Cdc7-IN-6) is a potent Cdc7 kinase inhibitor (IC50=4 nM) with antitumor activity as described in WO2019165473A1, compound I-D. Cdc7 is a serine threonine protein kinase enzyme that is essential for the initiation of DNA replication during the cell cycle.
M21177 (-)-Enitociclib (-)-Enitociclib ((-)-BAY-1251152) is an enantiomer of BAY-1251152 with a (-) spin. BAY-1251152 is a potent and highly selective inhibitor of cell cycle-dependent protein kinase (PTEF/CDK9).
M21148 (R)-CR8 trihydrochloride (R)-CR8 trihydrochloride, one of the isomers of CR8, is a potent CDK1/2/5/7/9 inhibitor with anti-proliferative and pro-apoptotic effects on CML cell lines. (R)-CR8 trihydrochloride inhibited CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM ), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM).
M21041 MS140 MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
M21040 BSJ-4-116 BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects.
M21000 LY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
M20882 G1T38 Lerociclib (G1T38) is a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor with IC50 values of 0.001 μM, 0.002 μM and 0.028 μM for CDK4, CDK6 and CDK9 respectively.
M20751 BRD6989 BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA).
M20705 AS2863619 AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells.
M20671 SGC-GAK-1 SGC-GAK-1 is a potent, selective, and cell-active inhibitor of cyclin G-associated kinase (GAK) with Ki value of 3.1 nM and >50-fold selectivity over nearest kinase.
M20650 SEL120-34A SEL120-34A is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8) with IC50 values of 4.4 nM and 10.4 nM for CDK8/Cyclin C and CDK19/CyclinC respectively.
M20357 WAY-352563 WAY-352563 is a CDK9 inhibitor.
M20332 WAY-383487 WAY-383487 is a CDK9 inhibitor.
M20326 WAY-381332 WAY-381332 is a Mimetic CDK9 inhibitor.
M20323 WAY-643018 WAY-643018 is a CDK1, CDK2, and CDK4 inhibitor.
M20271 WAY-652641 WAY-652641 is a CDK inhibitor.
M20265 WAY-648936 WAY-648936 is a CDK1, CDK2, and CDK4 inhibitor.

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.